NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 143 filers reported holding NEKTAR THERAPEUTICS in Q3 2013. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $169,862,000 | -9.9% | 13,843,692 | +26.2% | 0.03% | -20.5% |
Q3 2016 | $188,481,000 | +29.6% | 10,970,974 | +7.3% | 0.04% | +21.9% |
Q2 2016 | $145,452,000 | +5.5% | 10,221,478 | +1.9% | 0.03% | 0.0% |
Q1 2016 | $137,905,000 | -17.0% | 10,029,475 | +1.7% | 0.03% | -15.8% |
Q4 2015 | $166,103,000 | +54.8% | 9,857,716 | +0.7% | 0.04% | +35.7% |
Q3 2015 | $107,276,000 | -7.7% | 9,787,913 | +5.4% | 0.03% | 0.0% |
Q2 2015 | $116,205,000 | +117.0% | 9,288,975 | +90.8% | 0.03% | +115.4% |
Q1 2015 | $53,562,000 | -27.0% | 4,869,231 | +2.9% | 0.01% | -27.8% |
Q4 2014 | $73,367,000 | +41.2% | 4,733,348 | +9.9% | 0.02% | +20.0% |
Q3 2014 | $51,975,000 | -9.5% | 4,306,099 | -3.9% | 0.02% | -6.2% |
Q2 2014 | $57,442,000 | -2.6% | 4,480,672 | -7.9% | 0.02% | -5.9% |
Q1 2014 | $58,947,000 | +19.9% | 4,863,573 | +12.3% | 0.02% | +13.3% |
Q4 2013 | $49,165,000 | +7.5% | 4,331,732 | -1.1% | 0.02% | 0.0% |
Q3 2013 | $45,752,000 | +4.4% | 4,380,285 | +15.4% | 0.02% | -6.2% |
Q2 2013 | $43,840,000 | – | 3,795,654 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |